lifitegrast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
integrin antagonists 5174 1025967-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lifitegrast
  • SAR 1118-023
  • SAR 1118
  • SAR-1118
  • xiidra
a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
  • Molecular weight: 615.48
  • Formula: C29H24Cl2N2O7S
  • CLOGP: 2.28
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 133.99
  • ALOGS: -5.03
  • ROTB: 7
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,TEK,TGFBR1 22
kinase-selectivity-class AXL,BRAF,EIF2AK3,GRK2,MAP2K6,PDK1,TEK 7
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 11, 2016 FDA SHIRE DEV LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 2960.05 28.79 401 8752 529 90618765
Instillation site reaction 2313.71 28.79 300 8853 197 90619097
Eye irritation 1877.70 28.79 474 8679 33504 90585790
Vision blurred 1434.25 28.79 502 8651 109791 90509503
Dysgeusia 815.91 28.79 274 8879 52286 90567008
Eye pain 621.20 28.79 214 8939 43954 90575340
Instillation site pruritus 567.28 28.79 71 9082 17 90619277
Instillation site irritation 566.22 28.79 79 9074 144 90619150
Instillation site erythema 523.53 28.79 67 9086 32 90619262
Instillation site lacrimation 440.07 28.79 54 9099 3 90619291
Ocular hyperaemia 399.36 28.79 144 9009 33654 90585640
Dry eye 333.85 28.79 147 9006 57784 90561510
Lacrimation increased 318.47 28.79 115 9038 26947 90592347
Eye discharge 281.69 28.79 79 9074 8179 90611115
Instillation site discharge 265.17 28.79 33 9120 6 90619288
Instillation site swelling 218.61 28.79 27 9126 3 90619291
Product container issue 205.40 28.79 47 9106 2134 90617160
Eye pruritus 197.78 28.79 83 9070 28944 90590350
Ocular discomfort 190.47 28.79 55 9098 6315 90612979
Instillation site discomfort 169.43 28.79 21 9132 3 90619291
Blood folate decreased 168.11 28.79 38 9115 1632 90617662
Product quality issue 136.09 28.79 90 9063 79235 90540059
Product use complaint 135.16 28.79 37 9116 3496 90615798
Visual impairment 127.32 28.79 106 9047 132259 90487035
Eye disorder 106.40 28.79 53 9100 27337 90591957
Foreign body sensation in eyes 105.38 28.79 30 9123 3270 90616024
Instillation site dryness 103.13 28.79 13 9140 4 90619290
Eye swelling 102.88 28.79 53 9100 29333 90589961
Eyelid margin crusting 98.70 28.79 25 9128 1747 90617547
Instillation site burn 82.01 28.79 10 9143 0 90619294
Product packaging quantity issue 81.37 28.79 21 9132 1581 90617713
Instillation site foreign body sensation 79.39 28.79 10 9143 3 90619291
Instillation site inflammation 76.87 28.79 11 9142 26 90619268
Drug ineffective 69.52 28.79 299 8854 1383999 89235295
Product dose omission issue 68.76 28.79 113 9040 291574 90327720
Inappropriate schedule of product administration 65.22 28.79 78 9075 149855 90469439
Superficial injury of eye 61.92 28.79 13 9140 393 90618901
Swelling of eyelid 59.70 28.79 22 9131 5432 90613862
Product taste abnormal 59.36 28.79 18 9135 2442 90616852
Instillation site hypersensitivity 57.41 28.79 7 9146 0 90619294
Madarosis 52.48 28.79 18 9135 3611 90615683
Burning sensation 51.16 28.79 46 9107 63406 90555888
Instillation site paraesthesia 49.21 28.79 6 9147 0 90619294
Photophobia 48.67 28.79 29 9124 21240 90598054
Asthenopia 44.27 28.79 15 9138 2899 90616395
Erythema of eyelid 42.52 28.79 15 9138 3268 90616026
Abnormal sensation in eye 37.40 28.79 12 9141 1959 90617335
Joint swelling 36.78 28.79 4 9149 503296 90115998
Eyelid irritation 35.98 28.79 10 9143 998 90618296
Arthritis 33.03 28.79 60 9093 167255 90452039
Instillation site haemorrhage 32.80 28.79 4 9149 0 90619294
Vital dye staining cornea present 32.80 28.79 4 9149 0 90619294
Product storage error 32.34 28.79 22 9131 20219 90599075
Product delivery mechanism issue 32.33 28.79 8 9145 508 90618786
Product label issue 31.73 28.79 9 9144 967 90618327
Product packaging issue 31.17 28.79 10 9143 1631 90617663
Periorbital swelling 30.26 28.79 13 9140 4785 90614509
Taste disorder 30.03 28.79 34 9119 61512 90557782

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site reaction 611.18 78.36 67 1301 19 42619948
Vision blurred 548.40 78.36 154 1214 53545 42566422
Instillation site pain 510.62 78.36 58 1310 44 42619923
Eye irritation 454.50 78.36 98 1270 11220 42608747
Lacrimation increased 142.81 78.36 39 1329 11719 42608248
Instillation site lacrimation 130.93 78.36 14 1354 0 42619967
Eye pain 124.25 78.36 38 1330 16992 42602975
Instillation site erythema 99.45 78.36 11 1357 4 42619963
Ocular hyperaemia 88.86 78.36 29 1339 15934 42604033
Product quality issue 85.62 78.36 29 1339 17853 42602114

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 2329.27 32.11 292 5322 454 110583231
Instillation site reaction 1834.43 32.11 218 5396 139 110583546
Vision blurred 842.33 32.11 295 5319 128727 110454958
Eye irritation 631.25 32.11 173 5441 33279 110550406
Instillation site erythema 414.24 32.11 49 5565 27 110583658
Dysgeusia 398.16 32.11 145 5469 69840 110513845
Instillation site irritation 382.58 32.11 50 5564 123 110583562
Instillation site pruritus 362.14 32.11 42 5572 13 110583672
Instillation site lacrimation 305.67 32.11 35 5579 6 110583679
Eye pain 255.89 32.11 96 5518 50003 110533682
Ocular hyperaemia 225.31 32.11 82 5532 39204 110544481
Instillation site swelling 183.03 32.11 21 5593 4 110583681
Blood folate decreased 181.51 32.11 38 5576 2297 110581388
Lacrimation increased 164.09 32.11 61 5553 30889 110552796
Instillation site discomfort 160.02 32.11 18 5596 0 110583685
Instillation site discharge 156.41 32.11 18 5596 4 110583681
Eye discharge 154.21 32.11 43 5571 8711 110574974
Product quality issue 127.40 32.11 67 5547 77232 110506453
Product container issue 107.28 32.11 23 5591 1557 110582128
Eye pruritus 92.19 32.11 41 5573 32734 110550951
Dry eye 85.23 32.11 46 5568 55747 110527938
Instillation site burn 80.00 32.11 9 5605 0 110583685
Product dose omission issue 78.69 32.11 89 5525 321693 110261992
Visual impairment 66.81 32.11 55 5559 134373 110449312
Instillation site foreign body sensation 62.22 32.11 7 5607 0 110583685
Foreign body sensation in eyes 61.56 32.11 17 5597 3317 110580368
Eye swelling 61.17 32.11 31 5583 33017 110550668
Instillation site inflammation 59.54 32.11 8 5606 26 110583659
Eyelid margin crusting 54.98 32.11 14 5600 2002 110581683
Instillation site dryness 50.90 32.11 6 5608 3 110583682
Ocular discomfort 49.55 32.11 18 5596 8515 110575170
Drug ineffective 47.14 32.11 176 5438 1520364 109063321
Product use complaint 46.18 32.11 14 5600 3789 110579896
Instillation site paraesthesia 44.44 32.11 5 5609 0 110583685
Abnormal sensation in eye 44.32 32.11 12 5602 2174 110581511
Arthritis 43.70 32.11 48 5566 167538 110416147
Eye disorder 41.81 32.11 23 5591 28883 110554802
Photophobia 41.44 32.11 22 5592 25749 110557936
Inappropriate schedule of product administration 40.88 32.11 51 5563 203586 110380099
Ulcerative keratitis 39.05 32.11 13 5601 4753 110578932
Product packaging quantity issue 37.06 32.11 10 5604 1789 110581896
Instillation site hypersensitivity 35.56 32.11 4 5610 0 110583685

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01XA25 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
FDA MoA N0000192700 Lymphocyte Function-Associated Antigen-1 Antagonists
FDA EPC N0000192701 Lymphocyte Function-Associated Antigen-1 Antagonist
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:133024 lymphocyte function-associated antigen-1 antagonist

Related Drugs by ATC class:

S01XA Other ophthalmologicals 24 drugs
acetylcysteinealteplasealumascorbic acidavacincaptad pegolcenegerminciclosporindexpanthenoldiquafosolethylmorphineguaiazulenheparin show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.42 acidic
pKa2 12.3 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5% XIIDRA BAUSCH AND LOMB INC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8592450 May 17, 2026 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA BAUSCH AND LOMB INC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8367701 April 15, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA BAUSCH AND LOMB INC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 9447077 April 15, 2029 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA BAUSCH AND LOMB INC N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8168655 May 9, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Integrin alpha-L/beta-2 Adhesion ANTAGONIST IC50 8.05 SCIENTIFIC LITERATURE DRUG LABEL
Intercellular adhesion molecule 1 Antibody IC50 8.53 CHEMBL

External reference:

IDSource
038E5L962W UNII
D10374 KEGG_DRUG
4035938 VANDF
C3713860 UMLSCUI
CHEBI:133023 CHEBI
CHEMBL2048028 ChEMBL_ID
11965427 PUBCHEM_CID
DB11611 DRUGBANK_ID
CHEMBL2048409 ChEMBL_ID
9584 INN_ID
C575157 MESH_SUPPLEMENTAL_RECORD_UI
7533 IUPHAR_LIGAND_ID
720489009 SNOMEDCT_US
763569006 SNOMEDCT_US
243704 MMSL
31873 MMSL
016935 NDDF
1801820 RXNORM
038E5L962W INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 0078-0911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 24 sections
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 24208-911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 22 sections
Lifitegrast Human Prescription Drug Label 1 59651-450 FOR SOLUTION 50 mg OPHTHALMIC ANDA 22 sections